New predictive factors for chemosensitivity of breast cancers;Nouveaux facteurs prédictifs de chimiosensibilité dans le cancer du sein

Bulletin du Cancer

Volumn 95, Issue 10, 2008, Pages 943-950

  Bonnefoi, Hervé ^a   De Cremoux, Patricia ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT CURIE   (France)

Author keywords

Breast cancer; Chemosensitivity; Gene expression profiles; Response prediction

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PROTEIN P53; TAU PROTEIN;

BREAST CANCER; CHEMOSENSITIVITY; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; ONCOGENE; REVIEW; RISK FACTOR;

EID: 56149109880     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0729     Document Type: Review

References (59)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials. Lancet 2005 ; 365 : 1687-717.
2. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer : a meta-analysis of randomized trials. J Clin Oncol 2008 ; 26 : 44-53.
3. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003 ; 100 : 10393-8.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independenr gene expression data sets. Proc Natl Acad Sci USA 2003 ; 100 : 8418-23.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 ; 98 : 10869-74.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747-52.
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817-26.
8. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006 ; 24 : 3726-34.
9. Albain K, Barlow W, Shak S. Prognostic and predictive value of the 21-genes recurrence score assay in postmenopausal node-positive, ER-positive breast cancer (S8814, INTO100). Breast Cancer Res Treat 2007 ; 106 ; (abstr 10).
10. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogen- and progesterone-receptor status in ECOG 2197 : comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008 ; 26 : 2473-81.
11. Sparano JA. TAILORx : trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006 ; 7 : 347-50.
12. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008 ; 26 : 721-8.
13. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006 ; 98 : 1183-92.
14. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009.
15. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530-6.
16. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-ErbB-2 expression in breast cancer. J Clin Oncol 1992 ; 10 : 1049-56.
17. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998 ; 90 : 1346-60.
18. Arnould L, Fargeot P, Bonneterre J. Epirubicin dose response effect in node positive breast cancer patients is independent of HER2 overexpression : 10-year restrospective analysis of French Adjuvant Study Group 05 trial. Breast Cancer Res Treat 2003 ; 82 : S130 ; (Abstract 538).
19. Ravdin PM. How can prognostic and predictive factors in breast cancer be used in a pracrical way today? Recent Results Cancer Res 1998 ; 152 : 86-93.
20. Petit T, Wilt M, Veiten M, Millon R, Rodier JF, Botel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004 ; 40 : 205-11.
21. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003 ; 97 : 1758-65.
22. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001 ; 12 : 1081-9.
23. Di Leo A. The European experience with docetaxel in the treatment of early-stage breast cancer. Clin Breast Cancer 2002 ; 3(Suppl 2) : S59-S62.
24. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and copoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008 ; 26 : 736-44.
25. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007 ; 357 : 1496-506.
26. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil : Danish Breast Cancer Cooperative Group. J Clin Oncol 2005 ; 23 : 7483-90.
27. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et al. Diagnostic evaluation of HER-2 as a molecular target : an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005 ; 11 : 6598-607.
28. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer : a pooled analysis of randomized trials. J Natl Cancer Inst 2008 ; 100 : 14-20.
29. Larsimont D, Durbecq V, Awada A, Di Leo A. HER2 and topoisomerase II alpha : useful clinical markers in breast cancer. Bull Cancer 2008 ; 95(3) : 344-51.
30. Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol 2006 ; 4(suppl 1) : 4-9.
31. O'Malley F, Chia S, Tu D. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MAJ). J Clin Oncol 2006 ; 24(Suppl) ; (Abstract 533).
32. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993 ; 74 : 957-67.
33. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994 ; 266 : 807-10.
34. Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 1998 ; 4 : 1047-54.
35. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003 ; 22 : 7486-95.
36. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996 ; 2 : 811-4.
37. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-ErbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001 ; 61 : 2505-12.
38. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000 ; 6 : 50-6.
39. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002 ; 360 : 852-4.
40. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007 ; 4 : e90.
41. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995 ; 92 : 3963-7.
42. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer : prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996 ; 88 : 173-82.
43. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patienrs with node-positive breast cancer. JAMA 2006 ; 295 : 1658-67.
44. Andre F, Broglio K, Roché H, Martin M, Mackey JR, Penault-Llorca F, et al. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer : results from a pooled analysis. J Clin Oncol 2008 ; 26 : 2636-43.
45. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein tau : a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005 ; 102 : 8315-20.
46. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004 ; 22 : 2284-93.
47. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003 ; 362 : 362-9.
48. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005 ; 23 : 422-31.
49. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005 ; 23 : 3331-42.
50. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005 ; 23 : 7265-77.
51. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 ; 24 : 4236-44.
52. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006 ; 24 : 1839-45.
53. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006 ; 95 : 229-33.
54. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy : a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007 ; 8 : 1071-8.
55. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006 ; 12 : 1294-300.
56. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005 ; 23 : 7332-41.
57. Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F, et al. Prediction of metastatic relapse in node-positive breast cancer : establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat 2008 ; 109 : 491-501.
58. Pierga JY, Reis-Filho JS, Cleator SJ, Dexter T, Mackay A, Simpson P, et al. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 2007 ; 96 : 341-51.
59. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007 ; 9 : R81.